Minaris Regenerative Medicine’s leaders and experts are proud to share their knowledge and insight with the cell and gene therapy industry. Please review our current and past blog posts on topics of interest to this emerging industry.
Taking a new cell therapy from early clinical trials all the way to commercial manufacturing is a long and difficult process that few have completed to date. There are ...
CAR-T cell therapy presents numerous challenges for cell therapy developers who are looking to move towards commercialization. The move from development to commercial ...
Cell-based therapies are rapidly changing the way the medical industry is treating a wide range of diseases. As the development of these therapies continues to advance, ...
One of the most critical first steps in the development of many cell therapies is having optimized apheresis collections. Starting with variable or low-quality apheresis ...
On Thursday, February 23 from 2:00 – 3:30 PM EST, Sanjin Zvonic, PhD, PCT’s Senior Director, Business Leader, Clinical Cell Therapy Manufacturing, will be speaking as ...
The following is an excerpt from a paper originally published online in the journal Cytotherapy on October 26, 2016, entitled, “Bioreactors for cell therapies: Current ...
The following is an excerpt of an article I wrote that was originally published in the October 2016 issue of The Medicine Maker. Some companies still fail to look beyond ...
While using cell therapies that have a short shelf-life due to a “fresh” final product (meaning the product is not designed for long-term storage) is perfectly ...
This is the third in a three-part series (read Part 1 and Part 2 for the complete picture). As you approach cell therapy commercialization—having traveled what is still ...